Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICEA trial in early undifferentiated arthritis
NL-OMON29280Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of baricitinib, methotrexate, naproxen and methylprednisolone in undifferentiated arthritis (UA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Remission at 3 months and Sustained drug-free remission at 18 months. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
baricitinibmethotrexatenaproxenmethylprednisolone
03
Conditions
undifferentiated arthritis (UA)
Beyond the preview
Go deeper on NL-OMON29280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29280.